|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was a marked increase in COX-2 mRNA levels in 12 of 14 carcinomas (86%) compared with paired normal mucosa.
|
7926468 |
1994 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These results suggest that larger carcinomas produce more COX-2 to support their own growth and that COX-2 inhibitors may be effective agents of carcinoma growth suppression.
|
9809985 |
1998 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Two Cox genes have been cloned (Cox-1 and Cox-2), of which Cox-2 has recently been found to be expressed in several human carcinomas.
|
9823297 |
1998 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The ratio of tumor:paired normal mucosa of mRNA expression of ldlr and of cox-2 was measured in specimens taken during colonoscopy. ldlr and cox-2 transcripts were apparent in 11 of 11 carcinomas.
|
10471521 |
1999 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cox-2 mRNA expression was significantly increased in adenomas and carcinomas compared with normal mucosa (p < 0.005, p < 0.001, respectively).
|
10398082 |
1999 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The level of COX-2 mRNA was found to be elevated in carcinomas, relative to histologically normal pancreas from a healthy individual, as assessed by reverse transcription-PCR.
|
10485483 |
1999 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, expression of COX-2 was detected in malignant epithelial cells in 38% (17/47) of specimens with high-grade urothelial carcinomas.
|
10880372 |
2000 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These results indicate that Cox-2 is widely expressed in human bladder carcinomas and that the role of Cox-2 inhibition in bladder cancer should be further studied.
|
11827414 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 indices were significantly higher in gastric carcinoma tissues with deep invasion; indices for pT1, pT2, pT3, and pT4 carcinomas were 0.8 +/- 0.3, 2.8 +/- 0.5, 4.3 +/- 1.0, and 8.8 +/- 5.5, respectively (P < 0.05).
|
11346869 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There is now increasing evidence that a constitutive expression of COX-2 plays a role in development and progression of malignant epithelial tumors.
|
11196178 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent studies have shown overexpression of cyclooxygenase 2 (COX 2) and 5-lipoxygenase (5-lipox) in exocrine pancreatic carcinomas, suggesting a potential role of the arachidonic acid (AA) cascade in the regulation of this cancer type.
|
11238189 |
2001 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 expression was comparable in gastric stump carcinomas and conventional gastric carcinomas and localized primarily to the cytoplasm of the neoplastic cells.
|
11793368 |
2002 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of COX-2 and synthesis of PGE2 are up-regulated in cervical carcinomas.
|
12468638 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent evidence indicates that overexpression of the inducible cyclooxygenase, COX-2, is important in the pathogenesis of epithelial carcinomas.
|
11788675 |
2002 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
COX-2 gene product was evaluated immunohistochemically in 30 healthy persons, in 22 patients with dysplastic lesions without previous or concomitant carcinomas, and in 29 patients with oral carcinomas.
|
12747975 |
2003 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Moderate or strong epithelial COX-2 was present in 25% of hamartomas, including two hamartomas with dysplastic changes, and 64% of carcinomas.
|
12912958 |
2003 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The mRNA copy numbers for COX-2 were determined in 18 infiltrating carcinomas using quantitative RT-PCR and TaqMan methodology.
|
12740157 |
2003 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We investigated 5 gastric cancer cell lines and 58 primary gastric carcinomas for the presence of promoter hypermethylation in cox-2 gene.
|
12684668 |
2003 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Such directed apoptosis could eventually serve as a treatment for an entire class of Cox-2-overexpressing carcinomas.
|
12900768 |
2003 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
COX-2 staining was more intense in the carcinomas compared with normal epithelium (P < 0.001).
|
12738747 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of COX-2 was detected in 23 (82%) of 28 PJPs and in all carcinomas.
|
14623934 |
2003 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, PPARgamma protein was not detected in all of the eight carcinomas in which COX-2 protein was detected, suggesting that expression of PPARgamma and COX-2 was in a reciprocal relationship.
|
15266333 |
2004 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This suggests that COX-2 over-expression may be an early event in breast cancer aetiology permitting clones within the normal epithelium to evade apoptosis, to increase their numbers and perhaps acquire further changes that promote the formation of hyperplasias, and eventually carcinomas.
|
15642177 |
2005 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that overexpression of COX-2 is sufficient to cause hyperplasia and carcinomas in the urinary bladder.
|
15753378 |
2005 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
COX-2 protein expression was found in all carcinomas under analysis.
|
15958546 |
2005 |